Roden MM, Zaoutis TE, Buchanan WL, et a1. Epidemiology and outcome of zygomycosis: a review of 929 reported cases[J]. Clin Infect Dis, 2005, 41(5): 634-653．
[2]
Ruping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry[J]. J Antimicrob Chemother, 2010, 65(2): 296-302.
[3]
Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007[J]. Clin Microbiol Infect, 2011, 17(12): 1859-1867.
[4]
Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis: from bench to bedside[J]. Clin Infect Dis, 2009, 48(12): 1743-1751.
[5]
Zhao Y, Zhang Q, Li L, et al. Primary cutaneous mucormycosis caused by Rhizomucor variabilis in an immunocompetent patient[J]. Mycopathologia, 2009, 168(5): 243-247.
[6]
Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation[J]. J Clin Invest, 2007, 117(9): 2649-2657.
[7]
Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor[J]. Clin Infect Dis 1997, 24(2): 192-196.
[8]
Garcia-Diaz JB, Palau L, Pankey GA. Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor[J]. Clin Infect Dis, 2001, 32(12): e145-e150.
[9]
Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)[J]. Haematologica, 2013, 98(4): 492-504.
